TY - JOUR ID - TI - Clinicopathological Evaluation of CD44 Expression as a Proliferative Marker in Prostatic Adenocarcinoma AU - Wurood Abdullah Imran , Hadi Muhammad Ali Almosawi, Rafid Fakhir Al Husseini PY - 2021 VL - 20 IS - 2 SP - 165 EP - 171 JO - Iraqi Postgraduate Medical Journal المجلة العراقية للاختصاصات الطبية SN - 83601608 98932708 AB - BACKGROUND:Prostatic cancer is the 6th commonest cancer worldwide, and the 2nd commonest cancer amongmen. In Iraq, it is the fourth most common cancer and cause of cancer deaths in males.The commonest form of prostatic cancer is adenocarcinoma (75% of patients > 65 years).Prevalence of prostate cancer rises with age and hormonal causes. Core needle biopsy is a standardtechnique and largely preferred for non-operative diagnosis since it permits architectural andcytological assessment.OBJECTIVE:Immunohistochemical evaluation of CD44 expression in prostatic adenocarcinoma asa proliferative marker and correlate it with clinicopathological parameters (age, PSA level, andtumor grade).MATERIALS AND METHODS:Prostatic specimens were obtained via different procedures (TURP, and tru-cut biopsy). Formalinfixed paraffin embedded blocks from 50 patients with prostatic adenocarcinoma, histologicalsections taken for hematoxylin and eosin staining to determine histopathological features,monoclonal antibody for CD44 used for immunohistochemical staining of tissue sections andCD44 expression correlated with clinicopathological parameters (age, PSA level, and tumor grade).RESULTS:There was a significant inverse correlation between CD44 expression and Gleason grade score (i.e.high expression in low grade tumors), while there was no correlation between age and PSA levelwith CD44 expression.CONCLUSION:CD44 expression in prostatic adenocarcinoma can be utilized as a prognostic marker as it impliesless tumor aggressiveness with positive high expression which means lower grade tumor and betterdifferentiation.

ER -